Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model

Cell Stress and Chaperones

Volumn 16, Issue 4, 2011, Pages 449-457

  Pakravan, Nafiseh ^a   Hassan, Zuhair Mohammad ^b  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Adjuvant activity; Breast cancer; Gp96 terminal domains; Her2; Regulatory T cells; Tumor progression

Indexed keywords

DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GLYCOPROTEIN GP 96; INTERLEUKIN 4;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BREAST CANCER; CANCER IMMUNIZATION; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; GENE EXPRESSION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR GROWTH;

ADJUVANTS, PHARMACEUTIC; ANIMALS; BREAST NEOPLASMS; CANCER VACCINES; DISEASE MODELS, ANIMAL; FEMALE; INTERFERON-GAMMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; PROTEIN STRUCTURE, TERTIARY; RATS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

MUS; RATTUS;

EID: 80052455262     PISSN: 13558145     EISSN: 14661268     Source Type: Journal    
DOI: 10.1007/s12192-011-0258-6     Document Type: Review

References (44)

1. Beatty GL, Paterson Y (2000) IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J Immunol 165(10):5502-5508
2. Binder RJ (2008) Heat-shock protein-based vaccines for cancer and infectious disease. Expert Rev Vaccine 7:383-393 (Pubitemid 351520026)
3. Block MS, Markovic SN (2009) The tumor/immune interface: clinical evidence of cancer immunosurveillance, immunoediting and immunosubversion. Am J Immunol 5(1):29-49
4. Cappello P, Triebel F, Iezzi M, Caorsi C, Quaglino E, Lollini PL et al (2003) LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res 63:2518-2525 (Pubitemid 36605192)
5. Chang SY, Lee KC, Ko SY, Ko HJ, Kang CY (2004) Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. Int J Cancer 111:86-95 (Pubitemid 38859288)
6. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC (1994) Green fluorescent protein as a marker for gene expression. Science 263:802-805 (Pubitemid 24093206)
7. Dela Cruz JS, Morrison SL, Penichet ML (2005) Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein. Vaccine 23:4793-4803 (Pubitemid 41557330)
8. Disis ML, Scholler N, Dahlin A, Pullman J, Knutson KL, Hellström KE et al (2003) Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity. Mol Cancer Ther 2:995-1002
9. Facciponte JG, Wang XY, MacDonald IJ, Park JE, Arnouk H, Grimm MJ et al (2006) Heat shock proteins HSP70 and GP96: structural insights. Cancer Immunol Immunother 55(3):339-346 (Pubitemid 41682583)
10. He YF, Wang XH, Zhang GM, Chen HT, Zhang H, Feng ZH (2005) Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy. Cancer Immunol Immunother 54(9):891-897 (Pubitemid 40991331)
11. Ishikawa T, Kobayashi M, Mai M, Suzuki T, Ooi A (1997) Amplification of the c-erbB-2 (Her-2/neu) gene in gastric cancer cells. Am J Pathol 151:761-768
12. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD (1998) Demonstration of an interferon gammadependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95(13):7556-7561 (Pubitemid 28293291)
13. Kmieciak M, Knutson KL, Dumur CI, Manjili MH (2007) HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol 37:675-685 (Pubitemid 46916934)
14. Lepique AP, Regina K, Daghastanli P, Cuccovia IM, Villa LL (2009) HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin Cancer Res 15:4391-4400
15. Li H, Zhou M,Han J, Zhu X,Dong T, Gao GF et al (2005a) Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments. J Immunol 174:195-204 (Pubitemid 40007405)
16. Li HT, Yan JB, Li J, Zhou MH, Zhu XD, Zhang YX et al (2005b) Enhancement of humoral immune responses to HBsAg by heat shock protein gp96 and its N-terminal fragment in mice. World J Gastroenterol 11:2858-2863 (Pubitemid 40790051)
17. Lin CC, Chou CW, Shiau AL, Tu CF, Ko TM, Chen YL et al (2004) Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu. Mol Ther 10:290-301
18. Liu K, Caldwell SA, Abrams SI (2005) Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gammaregulated gene expression. Cancer Res 65(10):4376-4388 (Pubitemid 40775677)
19. Manjili MH, Kmieciak M (2008) Does HER-2/neu antigen loss in metastatic breast tumors occur under immune pressure? Int J Cancer 123(6):1476-1477
20. Marth C, Mueller-Holzner E, Greiter E, Cronauer MV, Zeimet AG, Doppler W et al (1990) Gamma-interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells. Cancer Res 50:7037-7041 (Pubitemid 20361110)
21. Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K et al (1997) Peptides derived from a wild-type murine protooncogene c-erbB-2/HER2/2 neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 159:1336-1343 (Pubitemid 127484112)
22. Nagaraj S, Gabrilovich DI (2008) Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 68:2561-2563 (Pubitemid 351556251)
23. Nicchitta CV (2003) Re-evaluating the role of heat-shock protein peptide interactions in tumour immunity. Nat Rev Immunol 3:427-432 (Pubitemid 37323202)
24. Nicchitta CV, Carrick DM, Baker-Lepain JC (2004) The messenger and the message: gp96GRP94)-peptide interactions in cellular immunity. Cell Stress Chaperones 9(4):325-331
25. Nishikawa H, Kato T, Tawara I, Ikeda H, Kuribayashi K, Allen PM et al (2005) IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response. J Immunol 175(7):4433-4440 (Pubitemid 41361979)
26. Orlandi F, Venanzi FM, Concetti A, Yamauchi H, Tiwari S, Norton L et al (2007) Antibody and CD8+ T cell responses against HER2/ neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine. Clin Cancer Res 13:6195-6203 (Pubitemid 350075081)
27. Pakravan N, Soleimanjahi H, Hassan ZM (2010a) GP96 C-terminal improves Her2/neu DNA vaccine. J Gene Med 12:345-353
28. Pakravan N, Soudi S, Hassan ZM (2010b) N-terminally fusion of Her2/neu to HSP70 decreases efficiency of Her2/neu DNA vaccine. Cell Stress Chaperones 15:631-638
29. Pakravan N, Langroudi L, Hajimoradi M, Hassan ZM (2010c) Coadministration of GP96 and Her2/neu DNA vaccine in a Her2 breast cancer model. Cell Stress Chaperones 15(6):977-984
30. Quaglino E, Mastini C, Iezzi M, Forni G, Musiani P, Klapper LN et al (2005) The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice. Vaccine 23:3280-3287 (Pubitemid 40523121)
31. Rapp UK, Kaufmann SH (2004) DNA vaccination with gp96-peptide fusion proteins induces protection against an intracellular bacterial pathogen. Int Immunol 16:597-605 (Pubitemid 38489434)
32. Rovero S, Amici A, Carlo ED, Bei R, Nanni P, Quaglino E et al (2000) DNA vaccination against rat Her-2/neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165(9):5133-5142
33. Sambrook J, Russell DW (2001) Molecular cloning: a laboratory manual, 3rd edn. Cold Spring Harbor Laboratory, Cold Spring Harbor, pp 1.38-1.41, 1.59-1.61
34. Shafer-Weaver KA, Anderson MJ, Stagliano K, Malyguine A, Greenberg NM, Hurwitz AA (2009) Cutting edge: tumorspecific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells. J Immunol 183:4848-4852
35. Shevach EM (2006) From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25:195-201 (Pubitemid 44224153)
36. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al1989) Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712 (Pubitemid 19147683)
37. Spadaro M, Ambrosino E, Iezzi M, Di Carlo E, Sacchetti P, Curcio C et al (2005) Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin Cancer Res 11:1941-1952 (Pubitemid 40471860)
38. Spoelstra FM, Postma DS, Hovenga H, Noordhoek JA, Kauffman HF (1999) Interferon-gamma and interleukin-4 differentially regulate ICAM-1 and VCAM-1 expression on human lung fibroblasts. Eur Respir J 14:759-766 (Pubitemid 29519333)
39. Srivastava P (2002) Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20:395-425 (Pubitemid 34293430)
40. Thornhill MH, Wellicome SM, Mahiouz DL, Lanchbury JS, Kyan-Aung U, Haskard DO (1991) Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding. J Immunol 146:592-598
41. Wang Y, Liu D, Chen P, Koeffler HP, Tong X, Xie D (2008) Negative feedback regulation of IFN-gamma pathway by IFN regulatory factor 2 in esophageal cancers. Cancer Res 68:1136-1143 (Pubitemid 351272232)
42. Wei WZ, Shi WP, Galy A, Lichlyter D, Hernandez S, Groner B et al (1999) Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 81:748-754 (Pubitemid 29214385)
43. Worschech A, Kmieciak M, Knutson KL, Bear HD, Szalay AA, Wang E et al (2008) Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res 68:2436-2446 (Pubitemid 351521819)
44. Yan J, Liu X, Wang Y, Jiang X, Liu H, Wang M et al (2007) Enhancing the potency of HBV DNA vaccines using fusion genes of HBV-specific antigens and the N-terminal fragment of gp96. J Gene Med 9:107-121 (Pubitemid 46444488)